mProX™ Human PVRIG Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1

Target Classification

Other Targets Drug Discovery Assays and Products

Gene ID

Human:79037

UniProt ID

Human:Q6DKI7

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Recent studies have highlighted the potential applications of PVRIG (CD112R) in various diseases. One study revealed an inverse causal relationship between Alzheimer's disease (AD) and cancer, with PVRIG upregulation identified as a risk factor for AD but a protective factor for cancer. Another study found that elevated CD112R and PD-1 expression levels in cytotoxic T lymphocytes located in T cell nests of colorectal cancer predicted favorable patient outcomes. In hepatocellular carcinoma (HCC), PVRIG expression was an independent prognostic factor and a potential target for immunotherapy. Additionally, the CD226 axis, which includes CD226, TIGIT, CD96, and PVRIG, has been implicated in cancer immunotherapy, with ongoing research on their therapeutic strategies and underlying biology. These findings suggest the potential of targeting PVRIG and the CD226 axis for the treatment of various diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PVRIG Stable Cell Line (S01YF-1023-PY284). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Miller (Verified Customer)

What is the role of PVRIG in tumor immunity? Feb 07 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

PVRIG acts as an inhibitory immune checkpoint in cancer, with its blockade shown to enhance anti-tumor immunity, particularly in NK cells. Feb 07 2022

chat Peyton Smith (Verified Customer)

How does PVRIG interact with other immune checkpoints like TIGIT and PD-1? Jul 22 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

PVRIG, TIGIT, and PD-1 pathways are non-redundant inhibitory signaling pathways in cancer, with combined blockade of these checkpoints potentially beneficial in cancer therapy. Jul 22 2023

Published Data

Fig.1 In the bone marrow of patients with acute myeloid leukemia, the expression of PVRIG is observed.

The expression of PVRIG on blasts or immune cell types in the bone marrow was assessed in acute myeloid leukemia (AML) patients (n=19-20) and healthy donors (n=13).

Ref: Li, Jessica, et al. "PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia." Haematologica 106.12 (2021): 3115.

Pubmed: 33147937

DOI: 10.3324/haematol.2020.258574

Research Highlights

Dong, Zehua. et al. "Mendelian randomization and transcriptomic analysis reveal an inverse causal relationship between Alzheimer's disease and cancer." Journal of translational medicine, 2023.
Alzheimer's disease (AD) and cancer are two prevalent age-related diseases that have been studied extensively. Recent epidemiological research has shown a correlation between the two, with a possible inverse relationship. Despite this evidence, the precise mechanism behind this relationship has not been fully explored. This highlights the need for further investigation into the potential mechanisms linking AD and cancer, in order to gain a better understanding of the relationship between these two diseases.
Dong, Zehua. et al. "Mendelian randomization and transcriptomic analysis reveal an inverse causal relationship between Alzheimer's disease and cancer." Journal of translational medicine, 2023.
Pubmed: 37542274 DOI: 10.1186/s12967-023-04357-3

Yang, Cheng. et al. "Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Nests of Colorectal Cancer." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2023.
A study was conducted to investigate the biological importance of focal aggregates of T lymphocytes in colorectal cancer. The researchers developed a deep learning-based framework that uses CD8, PD-1, CD112R, and Ki67 multiplex fluorescence immunohistochemistry to automatically identify T cell accumulations (T cell nests). The cohort of 523 colorectal cancer cases with clinical follow-up data was analyzed to assess the relevance of these parameters. Further spatial analysis revealed enriched CD8 and PD-1 T cell subsets. Results suggest that these parameters may have clinical significance in colorectal cancer.
Yang, Cheng. et al. "Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Nests of Colorectal Cancer." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2023.
Pubmed: 36788088 DOI: 10.1016/j.modpat.2022.100089